Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00745316 · ClinicalTrials.gov registry record · Phase 2
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00745316: Clinical Trial Phase 2 study, sponsored by Biogen.
NCT00745316 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00745316, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: * Disease related quality-of-life * Exercise capacity * Renal function * Concomitant medications
Interventions
- DRUG Placebo
- DRUG Tonapofylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Why NCT00745316 stopped before completion
NCT00745316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00745316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00745316 about?
NCT00745316 is a clinical study titled "Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency". The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: * Disease related quality-of-life * Exercise capacity * Renal function * Concomit...
What is the current status of trial NCT00745316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00745316?
The interventions under investigation include: Placebo (DRUG), Tonapofylline (DRUG).
Who is sponsoring clinical trial NCT00745316?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00745316's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia